Equities Analysts Set Expectations for MBRX FY2025 Earnings

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Equities research analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of Moleculin Biotech in a research report issued to clients and investors on Monday, March 24th. HC Wainwright analyst V. Bernardino now forecasts that the company will earn ($1.65) per share for the year, up from their prior estimate of ($3.31). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share.

Several other equities research analysts have also recently commented on the company. Maxim Group upgraded Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research note on Tuesday. StockNews.com upgraded shares of Moleculin Biotech to a “sell” rating in a report on Wednesday.

Moleculin Biotech Stock Performance

Shares of Moleculin Biotech stock opened at $1.04 on Thursday. Moleculin Biotech has a one year low of $0.40 and a one year high of $6.09. The stock’s 50-day moving average is $1.29 and its 200-day moving average is $1.98.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.